TABLE 1.
Baseline Demographics of Included Patients
| Variable | Intervention Group (n = 152) | Control Group (n = 304) | P Value |
|---|---|---|---|
| Trajectory, n (%) | |||
| Rapid decline | 24 (15.8) | 55 (18.1) | 0.729 |
| Gradual decline | 50 (32.9) | 104 (34.2) | |
| Gaps in adherence | 78 (51.3) | 145 (47.7) | |
| Sex, n (%) | |||
| Male | 56 (36.9) | 126 (41.4) | 0.344 |
| Female | 96 (63.2) | 178 (58.6) | |
| Age, n (%) | |||
| < 65 | 25 (16.5) | 53 (17.4) | 0.774 |
| 65-70 | 58 (38.2) | 111 (36.5) | |
| 71-75 | 40 (26.3) | 71 (23.4) | |
| > 75 | 29 (19.1) | 69 (22.7) | |
| Preferred language, n (%) | |||
| English | 150 (98.7) | 208 (68.4) | < 0.001 |
| Spanish | 2 (1.3) | 96 (31.6) | |
| Low-income subsidy, n (%) | |||
| No | 90 (59.2) | 142 (46.7) | 0.012 |
| Yes | 62 (40.8) | 162 (53.3) | |
| Physician specialty, n (%) | |||
| Primary care provider | 113 (74.3) | 235 (77.6) | 0.446 |
| Specialist | 39 (25.7) | 68 (22.4) | |
| Hyperlipidemia, n (%) | |||
| No | 14 (9.2) | 18 (5.9) | 0.195 |
| Yes | 138 (90.8) | 286 (94.1) | |
| Hypertension, n (%) | |||
| No | 10 (6.6) | 48 (15.8) | 0.005 |
| Yes | 142 (93.4) | 256 (84.2) | |
| Diabetes, n (%) | |||
| No | 74 (48.7) | 131 (43.1) | 0.258 |
| Yes | 78 (51.3) | 173 (56.9) | |
| Statin use for secondary prevention, n (%) | |||
| No | 12 (7.9) | 13 (4.3) | 0.110 |
| Yes | 140 (92.1) | 291 (95.7) | |
| Baseline PDC | |||
| Mean ± SD | 0.61 ± 0.20 | 0.56 ± 0.21 | 0.019 |
| Outcomes of interest in the follow-up | |||
| PDC in the follow-up | |||
| Mean ± SD | 0.67 ± 0.31 | 0.55 ± 0.36 | < 0.001 |
| PDC ≥ 0.8 in the follow-up, n (%) | |||
| No | 81 (53.3) | 202 (66.5) | 0.006 |
| Yes | 71 (46.7) | 102 (33.5) | |
| Statin discontinuation in the follow-up, n (%) | |||
| No | 137 (90.3) | 242 (79.6) | 0.005 |
| Yes | 15 (9.9) | 62 (20.4) | |
PDC = proportion of days covered; SD = standard deviation.